Viralytics R&D Tax rebate higher than expected
13 November, 2012 by Dylan Bushell-EmblingViralytics (ASX:VLA) has received nearly $1.5m as an R&D Tax Incentive rebate, and will plough the funds back into its oncolytic virus clinical development.
Vic Gov launches Technology Voucher Program
13 November, 2012 by AusBiotechGrowing on the success of the “Small Technologies Industry Uptake Program” the Victorian Government has launched a new “Technology Voucher Program” (TVP).
Biotron up after phase II HIV/HCV trial kicks off
12 November, 2012 by Dylan Bushell-EmblingBiotron (ASX:BIT) has commenced a pivotal phase II trial of BIT225 in patients with both HIV and HCV.
Viralytics trial shows Cavatak well-tolerated
12 November, 2012 by Dylan Bushell-EmblingViralyrics (ASX:VLA) has published results from a phase I trial showing anti-cancer virus, Cavatak, show the treatment was well-tolerated.
Photonz seeking partners to develop drug manufacturing process
12 November, 2012 by Dylan Bushell-EmblingAfter years in development, New Zealand's Photonz is embarking on the hunt for partners to help commercialise its manufacturing process for a key cardiovascular drug component.
BioDiem, Griffith Uni team for BDM-1 research
09 November, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) will collaborate with Griffith University's Institute of Glycomics to explore increasing the solubility of antimicrobial compound BDM-1.
Government IP report promotes research and business collaboration
09 November, 2012 by Tim DeanA report issued today by the Advisory Council on Intellectual Property has recommended reforming incentives to encourage researchers to collaborate with business.
DSMB clears Alchemia to continue cancer trial
08 November, 2012 by Dylan Bushell-EmblingThe DSMB overseeing Alchemia's phase III trial of HA-Irinotecan in metastatic colorectal cancer has recommended the trial continue on the strength of existing safety data.
IND lodged for Bionomics anxiety compound
08 November, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) US partner, Ironwood Pharmaceuticals, has lodged an Investigational New Drug application with the US FDA for anti-anxiety compound IW-2143 and has the go-ahead to conduct a phase I trial.
Australian biotech looking ‘healthy’ as it gathers for AusBiotech 2012
08 November, 2012 by AusBiotechThe AusBiotech 2012 national conference has again showcased the great talent and intellectual capital within Australia’s biotechnology industry.
Senz recruits first patient for leukaemia trial
07 November, 2012 by Dylan Bushell-EmblingSenz Oncology has recruited the first subject for the debut human trial of oral chemotherapeutic candidate VAL-1000 in patients with acute leukaemia.
Biota reaps $4.2m from R&D Tax Incentive
07 November, 2012 by Dylan Bushell-EmblingBiota (ASX:BTA) will add a $4.2m tax credit for the December quarter to its bottom line after receiving the funds through the R&D Tax Incentive.
Bioniche partner pulls plug on Urocidin trial
06 November, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) said its licensing partner has called off a phase III trial of Urocidin, a bladder cancer treatment, due in part to slow recruitment.
CSL trials new heart attack treatment
06 November, 2012 by Dylan Bushell-EmblingData from early studies of CSL's (ASX:CSL) lipoprotein-based treatment candidate show its potential in reducing the risk of recurrent heart attacks.
Australian colorectal cancer blood test attracts attention from US
05 November, 2012 by Dylan Bushell-EmblingQuest Diagnostics is evaluating using a biomarker-based blood test for colorectal cancer developed by Clinical Genomics, the CSIRO and the Flinders Centre for Innovation in Cancer.
